Metastatic ovarian cancer represents the most advanced form of the disease, where cancer cells have traveled beyond the ovaries to distant parts of the body, creating unique challenges for patients and their healthcare teams.

Understanding Metastatic Ovarian Cancer

Metastatic ovarian cancer is cancer that has spread from the ovaries or fallopian tubes to parts of the body outside the original site. When ovarian cancer reaches this stage, it is classified as Stage IV, the most advanced level of the disease. This means that cancer cells have moved beyond the pelvis and abdomen to more distant locations such as the lungs, the fluid around the lungs, the inside of the liver, or lymph nodes outside the abdomen.^[1]

The journey of ovarian cancer through the body is different from many other cancers. While most cancers spread through the bloodstream, ovarian cancer primarily moves through the peritoneal cavity—the space inside the abdomen lined by a membrane called the peritoneum. Cancer cells can detach from the primary tumor and are carried throughout this cavity by the natural fluid that exists there. This unique pattern of spread makes ovarian cancer particularly challenging because it can seed multiple areas within the abdomen before moving to more distant sites.^[3]

When cancer is found outside the ovary, doctors distinguish between locally advanced disease and metastatic disease. Locally advanced means the cancer has spread to other parts of the pelvis, while metastatic indicates it has reached more distant sites. This distinction matters because it affects treatment decisions and expected outcomes.^[1]

Epidemiology

Ovarian cancer affects a substantial number of women worldwide. In the United States alone, approximately 21,550 new cases of epithelial ovarian cancer are diagnosed each year, with about 14,600 deaths occurring as a result of the disease. This makes ovarian cancer the gynecologic malignancy with the highest case-to-fatality ratio—meaning it has one of the worst death rates compared to diagnosis rates among cancers affecting the female reproductive system.^[3]

The high mortality rate is largely explained by the fact that the majority of patients—approximately 75 percent—are diagnosed when the disease has already spread widely throughout the peritoneal cavity. This late-stage diagnosis means that more than 70 percent of women already have metastatic disease by the time they receive their diagnosis. Only about 20 percent of cases are caught in early stages when the cancer is still confined to the ovaries.^[3][4]

Globally, ovarian cancer is recognized as the fifth leading cause of cancer-related death among women and is one of the most common gynecological cancers worldwide. The disease shows a particularly poor prognosis, with 69 percent of all patients eventually succumbing to their disease. This stands in stark contrast to breast cancer, where only 19 percent of patients die from the disease.^[3]

Survival rates vary dramatically depending on the stage at diagnosis. Women diagnosed with Stage I ovarian cancer have a five-year survival rate of 90 percent, while those with Stage II have a 70 percent survival rate. However, when the disease reaches Stage III, the five-year survival rate drops to 39 percent. For Stage IV metastatic ovarian cancer, the survival rates vary by cancer type but remain significantly lower than earlier stages.^[1][10]

How Ovarian Cancer Spreads

The pattern of spread in ovarian cancer follows a generally predictable path, though there is no single trajectory that applies to every patient. Most commonly, if not caught in early stages, ovarian cancer moves from the pelvis to more distant parts of the abdomen and peritoneal cavity, then to the lymph nodes, and eventually to the liver. As the disease progresses further without successful treatment, it can reach the lungs, the fluid around the lungs, or tissue inside the liver.^[1][10]

The process begins when cancer cells break away from the original tumor on the ovary or fallopian tube. These cells can spread through the body in several ways. They may extend directly through the pelvis and abdomen to nearby organs such as the bladder, colon, or uterus. They can also travel through the lymphatic system, which is part of the body’s immune system, or less commonly through the bloodstream.^[6]

One distinctive feature of ovarian cancer metastasis is that it often spreads without entering blood vessels first. Because ovarian tumors lack a strong anatomical barrier, cancer cells can metastasize directly into the peritoneal cavity. Once there, they are carried by the physiological peritoneal fluid throughout the abdomen. This peritoneal metastasis increases the chance of ovarian cancer cells spreading to more distant organs over time.^[4]

During the initial spread, ovarian cancer cells undergo what scientists call an epithelial-to-mesenchymal transition. This is a process where cells change their characteristics to become more mobile and better able to survive in new locations. These cells often cluster together forming structures called spheroids, which helps them overcome a normal process called anoikis—a type of cell death that typically occurs when cells become detached from their surrounding tissue. The cancer cells prefer to attach to specific areas, particularly the abdominal peritoneum and omentum (a fatty tissue that covers the bowel).^[3]

The omentum, normally a soft fat pad covering the bowel and abdominal cavity, is almost always transformed by tumor in advanced cases. This causes significant pain for patients because the tumor in this location tends to compress and obstruct the bowel. The extensive seeding of the peritoneal cavity by tumor cells is often associated with ascites—a buildup of fluid in the abdomen—particularly in advanced, high-grade serous carcinomas that grow rapidly and metastasize early.^[3]

Unlike most other cancers, ovarian cancer rarely spreads through blood vessels to distant sites, though pelvic and para-aortic lymph nodes can become involved. Late-stage metastasis is characterized by fast growth of tumor nodules on surfaces covered by mesothelium, causing ascites, bowel obstruction, and tumor cachexia—a wasting syndrome that causes weakness and significant loss of body weight.^[3]

Causes

The development of ovarian cancer and its progression to metastatic disease involves numerous genetic and epigenetic changes that lead to cancer cell transformation. Scientists have identified that ovarian cancer could originate from any of three potential sites: the surfaces of the ovary itself, the fallopian tube, or the mesothelium-lined peritoneal cavity. This makes pinpointing a single cause challenging.^[3]

Once initiated, ovarian cancer development follows one of two main pathways. Type I tumors progress through a stepwise mutation process from a slow-growing borderline tumor to a well-differentiated carcinoma. Type II tumors, on the other hand, involve genetically unstable high-grade serous carcinomas that metastasize rapidly. These Type II cancers are particularly aggressive and are responsible for most ovarian cancer deaths.^[3]

The tumor microenvironment—the surrounding environment where the tumor grows—plays a crucial role in the development and spread of metastatic ovarian cancer. This environment includes various immune cells and important signaling pathways such as TGF-β, NF-κB, and PI3K/AKT/mTOR, which help cancer cells survive and grow. Understanding how these pathways work together is critical for developing more effective treatments.^[8]

An important aspect of metastatic spread involves epigenetic changes rather than just genetic mutations. Epigenetic changes refer to modifications in how genes are expressed without changing the DNA sequence itself. Metastasizing ovarian cancer cells adapt to new environments they encounter, and this adaptation often takes advantage of epigenetic processes. This is one reason why some cancers become resistant to treatments that target genetic changes alone.^[4]

Risk Factors

While the sources provided do not extensively detail specific risk factors for developing metastatic ovarian cancer versus early-stage disease, several factors increase the overall risk of developing ovarian cancer, which can then progress to metastatic stages if not detected and treated early.

The lack of an anatomical barrier in ovarian tumors is considered a structural factor that facilitates direct metastasis into the peritoneal cavity. This unique characteristic of the ovaries makes it easier for cancer cells to escape the original tumor site compared to cancers in organs with stronger physical boundaries.^[4]

Symptoms

The symptoms of metastatic ovarian cancer can be severe and significantly impact a patient’s quality of life. When ovarian cancer spreads, it causes symptoms both from the original tumor and from the areas where it has metastasized.

Common symptoms of ovarian cancer, which persist and worsen as the disease becomes metastatic, include abdominal bloating or swelling, quickly feeling full when eating, discomfort in the pelvic area, fatigue, back pain, and changes in bowel habits such as constipation. Patients may also experience a frequent need to urinate and unexplained weight loss.^[5]

One of the challenges with ovarian cancer symptoms is that they are often attributed to other, more common conditions, which contributes to late diagnosis. The symptoms can mimic hormonal fluctuations during menopause or chronic diseases like endometriosis, making it difficult for both patients and doctors to recognize the cancer in its early stages.^[6]

When cancer spreads to specific organs, additional symptoms appear. If it spreads to the lungs or the space around the lungs, patients may experience shortness of breath and cough. Spread to the liver can cause liver function problems. Bowel involvement is particularly common and problematic, as the cancer often sits on the outside of the bowels, leading to bowel obstruction—a serious condition where patients cannot have bowel movements and experience nausea and vomiting.^[16]

Advanced metastatic cancer often causes ascites—fluid buildup in the abdomen—which leads to increased abdominal swelling, discomfort, and difficulty breathing as the fluid presses on the diaphragm. This is one of the most distressing symptoms for patients with widespread peritoneal metastasis.^[3]

Physical symptoms in advanced stages may also include constipation, fever, feeling cold, irregular heartbeat, low blood pressure, delirium, hallucinations, and trouble swallowing. These symptoms reflect how extensively the cancer has affected the body’s normal functioning.^[20]

Prevention

The sources provided do not contain specific information about preventing metastatic ovarian cancer or preventing the spread of existing ovarian cancer. Prevention strategies would primarily focus on early detection of ovarian cancer before it reaches metastatic stages, but specific preventive measures are not detailed in these sources.

Pathophysiology

The pathophysiology of metastatic ovarian cancer involves complex changes in how cells function and interact with their environment. During the initial stages of tumor development and metastasis, ovarian cancer cells undergo significant transformations that allow them to survive and thrive in new locations throughout the body.

A key change involves the expression of adhesion molecules. During metastasis, there is a change in cadherin and integrin expression—proteins that help cells stick to each other and to surrounding structures. Cancer cells also up-regulate proteolytic pathways, which involve enzymes that break down proteins in the surrounding tissue, making it easier for cancer cells to invade new areas.^[3]

When cancer cells first break away and float in the peritoneal fluid, they form spheroids—clusters of cells that protect each other from dying. These spheroids overcome anoikis, which is the normal cell death that should occur when cells lose contact with their proper tissue environment. This survival mechanism is crucial for metastatic spread.^[3]

Once the cancer cells reach their destination—often the peritoneum or omentum—they undergo a reversal of their earlier transformation. They revert to a more epithelial phenotype, meaning they become more like the cells they originated from. This allows them to establish themselves and begin forming new tumor nodules. The initial steps of metastasis are carefully regulated by controlled interactions between adhesion receptors and proteases (protein-breaking enzymes).^[3]

Late metastasis is characterized by oncogene-driven fast growth of tumor nodules on mesothelium-covered surfaces. These rapidly proliferating tumors compress vital organs and, while initially responsive to chemotherapy, they typically become resistant over time. This rapid growth and the development of chemotherapy resistance contribute to why ovarian cancer has such a deadly course despite treatment advances.^[3]

The tumor microenvironment plays an active role in supporting metastatic growth. Various signaling pathways within this environment—including TGF-β, NF-κB, and PI3K/AKT/mTOR—help cancer cells evade the immune system, continue growing, and resist treatment. Understanding these pathways has become a focus for developing new targeted therapies.^[8]

An important discovery in recent research involves proteins found in tumors called G9a and EZH2. These proteins protect cancer cells from attacks by healthy immune cells, allowing the tumors to grow and spread. By blocking these proteins, researchers have found that immune cells can be reactivated to fight cancer cells more effectively, offering hope for new combination treatments.^[4]